Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

The key distinction is value capture, not which disease market grows faster. GLP-1 adoption can expand while Novo’s economics disappoint: payer negotiations and competition may transfer part of the category’s growth to patients, payers, and rivals. The pill could broaden access, but check whether it adds treated patients or mainly shifts existing demand from injectables before capitalizing it as incremental growth. Manufacturing capacity and net pricing are therefore more useful near-term indicators than headline demand.

Novo’s 2026 earnings contraction, if realized, is a near-term hurdle to its recovery narrative; evidence of durable prescription growth and stable net prices would matter more than broad estimates of the addressable market. The article’s positive view also relies on claims about product superiority and launch success that need verification against prescription, access, and safety data. For Bristol Myers Squibb, a low multiple and cash generation may offer downside support, but patent exposure and uncertain offsets make a cheap stock an uncertain catalyst. Its projected earnings rebound should be tested against product-level growth and cash conversion, not taken as proof the patent transition is solved.

Contrarian point: category growth does not guarantee Novo shareholder returns, but the reported 2026 slowdown alone does not establish a value trap. Avoid treating BMY’s low multiple as a clean hedge for Novo: their main risks differ, and BMY’s earnings recovery could surprise positively. The comparison also needs verification of cash-flow definitions and forecast periods before using the quoted metrics in relative valuation.